|1.||Morgan, Michael: 1 article (06/2010)|
|2.||Al-Shamma, Hussien: 1 article (06/2010)|
|3.||Strah-Pleynet, Sonja: 1 article (06/2010)|
|4.||Ullman, Brett: 1 article (06/2010)|
|5.||Semple, Graeme: 1 article (06/2010)|
|6.||Connolly, Daniel T: 1 article (06/2010)|
|7.||Teegarden, Bradley R: 1 article (06/2010)|
|8.||Casper, Martin D: 1 article (06/2010)|
|9.||Webb, Robert R: 1 article (06/2010)|
|10.||Pham, Lan: 1 article (06/2010)|
02/01/2010 - "5HT2A receptor inhibition with APD791, even when initiated after the onset of recurrent thrombosis, improves coronary patency in the in vivo canine model."
02/01/2010 - "APD791 attenuated recurrent thrombosis, irrespective of the time of treatment: in both protocols, flow-time area (index of coronary patency; normalized to baseline coronary flow) averaged 58-59% (P<0.01) following administration of APD791 vs. 21-28% in saline controls. "
02/01/2010 - "Protocol 2 was similar, except that: (i) treatment with APD791 or saline was begun 1 h after the onset of recurrent thrombosis; (ii) template bleeding time was measured; and (iii) blood samples were obtained for in vitro flow cytometric assessment of platelet responsiveness to serotonin. "
06/10/2010 - "Discovery and structure-activity relationship of 3-methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide (APD791): a highly selective 5-hydroxytryptamine2A receptor inverse agonist for the treatment of arterial thrombosis."
|2.||Serotonin (5 Hydroxytryptamine)